VYNE Therapeutics Inc [VYNE] stock is trading at $0.35, saw in change for the day. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VYNE shares have lost -4.79% over the last week, with a monthly amount drifted -73.06%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
VYNE Therapeutics Inc [NASDAQ: VYNE] stock has seen the most recent analyst activity on July 31, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, BTIG Research started tracking the stock with Buy rating on November 18, 2024, and set its price target to $8.
VYNE Therapeutics Inc [VYNE] stock has fluctuated between $0.33 and $4.30 over the past year. Currently, Wall Street analysts expect the stock to reach $5.75 within the next 12 months. VYNE Therapeutics Inc [NASDAQ: VYNE] shares were valued at $0.35 at the most recent close of the market. An investor can expect a potential return of 1542.86% based on the average VYNE price forecast.
Analyzing the VYNE fundamentals
VYNE Therapeutics Inc [NASDAQ:VYNE] reported sales of 0.60M for the trailing twelve months, which represents a growth of 106.12%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -75.13%, Pretax Profit Margin comes in at -69.69%, and Net Profit Margin reading is -69.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.75, Equity is -0.72 and Total Capital is -1.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3344 points at the first support level, and at 0.3213 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3603, and for the 2nd resistance point, it is at 0.3731.
Ratios To Look Out For
For context, VYNE Therapeutics Inc’s Current Ratio is 4.47. Also, the Quick Ratio is 4.47, while the Cash Ratio stands at 2.3. Considering the valuation of this stock, the price to sales ratio is 9.65, the price to book ratio is 0.13.
Transactions by insiders
Recent insider trading involved LEPORE PATRICK G, Director, that happened on Jan 15 ’25 when 15000.0 shares were purchased.
